By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Oncology is the subject of a report. According to news originating from Oxford, United Kingdom, by NewsRx correspondents, research stated, "Emerging developments in nanomedicine allow the development of genome-based technologies for non-invasive and individualised screening for diseases such as colorectal cancer. The main objective of this study was to measure user preferences for colorectal cancer screening using a nanopill."
Our news journalists obtained a quote from the research from the University of Oxford, "A discrete choice experiment was used to estimate the preferences for five competing diagnostic techniques including the nanopill and iFOBT. Alternative screening scenarios were described using five attributes namely: preparation involved, sensitivity, specificity, complication rate and testing frequency. Fourteen random and two fixed choice tasks, each consisting of three alternatives, were offered to 2225 individuals. Data were analysed using the McFadden conditional logit model. Thirteen hundred and fifty-six respondents completed the questionnaire. The most important attributes (and preferred levels) were the screening technique (nanopill), sensitivity (100%) and preparation (no preparation). Stated screening uptake for the nanopill was 79%, compared to 76% for iFOBT. In the case of screening with the nanopill, the percentage of people preferring not to be screened would be reduced from 19.2% (iFOBT) to 16.7%. Although the expected benefits of nanotechnology based colorectal cancer screening are improved screening uptake, assuming more accurate test results and less preparation involved, the relative preference of the nanopill is only slightly higher than the iFOBT."
According to the news editors, the research concluded: "Estimating user preferences during the development of diagnostic technologies could be used to identify relative performance, including perceived benefits and harms compared to competitors allowing for significant changes to be made throughout the process of development."
For more information on this research see: Public stated preferences and predicted uptake for genome-based colorectal cancer screening. BMC Medical Informatics and Decision Making, 2014;14():1-10. BMC Medical Informatics and Decision Making can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Medical Informatics and Decision Making - www.biomedcentral.com/bmcmedinformdecismak/)
The news correspondents report that additional information may be obtained from C.G.M. Groothuis-Oudshoorn, University of Oxford, Nuffield Dept. of Populat Hlth, Hlth Econ Res Center, Oxford, United Kingdom. Additional authors for this research include J.M. Fermont, J.A. van Til and M.J. IJzerman (see also Oncology).
Keywords for this news article include: Oxford, Europe, Genetics, Oncology, Colorectal, Technology, Colon Cancer, United Kingdom, Gastroenterology
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC